July 23, 2014 9:37 AM ET

Biotechnology

Company Overview of Enanta Pharmaceuticals, Inc.

Company Overview

Enanta Pharmaceuticals, Inc., a biotechnology company, is engaged in the development of small molecule drugs for the infectious disease field. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products comprising EDP-788 for the treatment of methicillin-resistant Staphylococcus aureus ba...

500 Arsenal Street

Watertown, MA 02472

United States

Founded in 1995

44 Employees

Phone:

617-607-0800

Fax:

617-607-0530

Key Executives for Enanta Pharmaceuticals, Inc.

Chief Executive Officer
Age: 58
Total Annual Compensation: $683.9K
Chief Financial Officer
Age: 59
Total Annual Compensation: $420.2K
Chief Scientific Officer and Senior Vice President of Research & Development
Age: 62
Total Annual Compensation: $486.4K
Compensation as of Fiscal Year 2013.

Enanta Pharmaceuticals, Inc. Key Developments

Enanta Pharmaceuticals, Inc. Announces U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Regimen for Genotype 1 Chronic Hepatitis C

Enanta Pharmaceuticals, Inc. announced that the New Drug Application for AbbVie's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review. The three direct-acting antiviral investigational regimen consists of the fixed-dose combination of ABT-450/ritonavir (150/100mg) co-formulated with ombitasvir (ABT-267) 25mg, dosed once daily, and dasabuvir (ABT-333) 250mg with or without ribavirin (weight-based), dosed twice daily. ABT-450 is Enanta's lead protease inhibitor developed through Enanta's collaboration with AbbVie. The NDA was submitted on April 21, 2014 and is supported by data from a large clinical program being conducted by AbbVie, including six phase 3 studies of more than 2,300 GT1 patients in over 25 countries. The regimen was granted a Breakthrough Therapy designation by the FDA in May 2013, a status given to investigational treatments for serious or life-threatening conditions with preliminary clinical evidence demonstrating substantial improvement on at least one clinically significant endpoint compared to available therapy. In May 2014, AbbVie submitted marketing authorization applications (MAAs) for regulatory approval in the European Union.

Enanta Pharmaceuticals, Inc. Presents at Boston CEO Conference, Jun-05-2014 02:00 PM

Enanta Pharmaceuticals, Inc. Presents at Boston CEO Conference, Jun-05-2014 02:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Speakers: Jay R. Luly, Chief Executive Officer, President and Director.

Enanta Pharmaceuticals, Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2014

Enanta Pharmaceuticals, Inc. announced consolidated earnings results for the second quarter and six months ended March 31, 2014. For the quarter, the company announced revenue of $2,160,000 compared to $1,196,000 for the same period a year ago. Loss from operations was $5,127,000 compared to $4,001,000 for the same period a year ago. Net loss was $5,203,000 compared to $3,749,000 for the same period a year ago. Net loss attributable to common stockholders was $5,203,000 or $0.28 per diluted share compared to $4,993,000 or $2.28 per diluted share for the same period a year ago. The changes in revenue for the three and six-month periods were primarily related to the timing and amount of milestone and other payments from collaborations, which have varied significantly from period to period and are expected to continue to do so. For the six months, the company announced revenue of $3,053,000 compared to $29,055,000 for the same period a year ago. Loss from operations was $10,584,000 compared to income from operations of $17,908,000 for the same period a year ago. Net loss was $10,573,000 compared to net income of $18,208,000 for the same period a year ago. Net loss attributable to common stockholders was $10,573,000 or $0.58 per diluted share compared to net income attributable to common stockholders of $2,012,000 or $1.09 per diluted share for the same period a year ago.

Similar Private Companies By Industry

Company Name Region
AndroScience Corporation United States
NanoFex LLC United States
ProChon Biotech Ltd. United States
ImmunGene Inc. United States
Vivacelle Bio, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Enanta Pharmaceuticals, Inc., please visit www.enanta.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.